DK1686999T3 - Pyrazolderivater som inhibitorer af receptortyrosinkinaser - Google Patents
Pyrazolderivater som inhibitorer af receptortyrosinkinaserInfo
- Publication number
- DK1686999T3 DK1686999T3 DK04798505T DK04798505T DK1686999T3 DK 1686999 T3 DK1686999 T3 DK 1686999T3 DK 04798505 T DK04798505 T DK 04798505T DK 04798505 T DK04798505 T DK 04798505T DK 1686999 T3 DK1686999 T3 DK 1686999T3
- Authority
- DK
- Denmark
- Prior art keywords
- inhibitors
- receptor tyrosine
- tyrosine kinases
- pyrazole derivatives
- pyrazole
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title 1
- 150000003217 pyrazoles Chemical class 0.000 title 1
- 102000027426 receptor tyrosine kinases Human genes 0.000 title 1
- 108091008598 receptor tyrosine kinases Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US52058103P | 2003-11-17 | 2003-11-17 | |
US55621304P | 2004-03-25 | 2004-03-25 | |
PCT/GB2004/004784 WO2005049033A1 (en) | 2003-11-17 | 2004-11-15 | Pyrazole derivatives as inhibitors of receptor tyrosyne kinases |
Publications (1)
Publication Number | Publication Date |
---|---|
DK1686999T3 true DK1686999T3 (da) | 2009-10-05 |
Family
ID=34623139
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK04798505T DK1686999T3 (da) | 2003-11-17 | 2004-11-15 | Pyrazolderivater som inhibitorer af receptortyrosinkinaser |
Country Status (26)
Country | Link |
---|---|
US (2) | US20070142413A1 (pt) |
EP (1) | EP1686999B1 (pt) |
JP (2) | JP4942486B2 (pt) |
KR (2) | KR101192939B1 (pt) |
AR (1) | AR046779A1 (pt) |
AT (1) | ATE435017T1 (pt) |
AU (1) | AU2004290948B2 (pt) |
BR (1) | BRPI0416605A (pt) |
CA (1) | CA2545527C (pt) |
CY (1) | CY1110498T1 (pt) |
DE (1) | DE602004021844D1 (pt) |
DK (1) | DK1686999T3 (pt) |
ES (1) | ES2328042T3 (pt) |
HK (1) | HK1092723A1 (pt) |
HR (1) | HRP20090454T1 (pt) |
IL (1) | IL175487A (pt) |
MY (1) | MY141220A (pt) |
NO (1) | NO20062188L (pt) |
NZ (1) | NZ547938A (pt) |
PL (1) | PL1686999T3 (pt) |
PT (1) | PT1686999E (pt) |
RU (1) | RU2413727C2 (pt) |
SI (1) | SI1686999T1 (pt) |
TW (1) | TWI343383B (pt) |
UY (1) | UY28623A1 (pt) |
WO (1) | WO2005049033A1 (pt) |
Families Citing this family (119)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE0104140D0 (sv) * | 2001-12-07 | 2001-12-07 | Astrazeneca Ab | Novel Compounds |
BRPI0406761A (pt) | 2003-01-14 | 2005-12-20 | Arena Pharm Inc | Derivados de arila e heteroarila 1,2,3-trissubstituìdos como moduladores do metabolismo e a profilaxia e tratamento de distúrbios relacionados a estes tais como diabetes e hiper-glicemia |
TW200530235A (en) | 2003-12-24 | 2005-09-16 | Renovis Inc | Bicycloheteroarylamine compounds as ion channel ligands and uses thereof |
US7793137B2 (en) | 2004-10-07 | 2010-09-07 | Cisco Technology, Inc. | Redundant power and data in a wired data telecommunincations network |
US7713973B2 (en) | 2004-10-15 | 2010-05-11 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
ATE519759T1 (de) | 2004-12-30 | 2011-08-15 | Exelixis Inc | Pyrimidinderivate als kinasemodulatoren und anwendungsverfahren |
DK1846394T3 (da) * | 2005-02-04 | 2012-01-16 | Astrazeneca Ab | Pyrazolylaminopyridinderivater, der er egnede som kinaseinhibitorer |
WO2006087530A1 (en) * | 2005-02-16 | 2006-08-24 | Astrazeneca Ab | Chemical compounds |
US7297700B2 (en) | 2005-03-24 | 2007-11-20 | Renovis, Inc. | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof |
US20090005396A1 (en) * | 2005-04-27 | 2009-01-01 | Astrazeneca Ab | Use of Pyrazolyl-Pyrimidine Derivatives in the Treatment of Pain |
US7745451B2 (en) | 2005-05-04 | 2010-06-29 | Renovis, Inc. | Tetrahydronaphthyridine and tetrahydropyrido[4,3-d]pyrimidine compounds and compositions thereof useful in the treatment of conditions associated with neurological and inflammatory disorders and dysfunctions |
KR20080015409A (ko) | 2005-05-16 | 2008-02-19 | 아스트라제네카 아베 | 티로신 키나제 억제제로서 유용한 피라졸릴아미노피리미딘 유도체 |
US8119655B2 (en) | 2005-10-07 | 2012-02-21 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
CN101346371B (zh) * | 2005-10-28 | 2012-11-14 | 阿斯利康(瑞典)有限公司 | 癌症治疗中用作酪氨酸激酶抑制剂的4-(3-氨基吡唑)嘧啶衍生物 |
JP2009513615A (ja) | 2005-10-28 | 2009-04-02 | アストラゼネカ アクチボラグ | 癌の治療においてチロシンキナーゼ阻害剤として使用するための4−(3−アミノピラゾール)ピリミジン誘導体 |
NZ594385A (en) * | 2005-11-03 | 2013-02-22 | Vertex Pharma | Aminopyrimidines useful as kinase inhibitors |
US7514435B2 (en) * | 2005-11-18 | 2009-04-07 | Bristol-Myers Squibb Company | Pyrrolotriazine kinase inhibitors |
ES2612196T3 (es) | 2005-12-13 | 2017-05-12 | Incyte Holdings Corporation | Pirrolo[2,3-b]piridinas y pirrolo[2,3-b]pirimidinas sustituidas con heteroarilo como inhibidores de quinasas Janus |
EP1971611B1 (en) | 2005-12-21 | 2012-10-10 | Abbott Laboratories | Anti-viral compounds |
WO2007076034A2 (en) * | 2005-12-21 | 2007-07-05 | Abbott Laboratories | Anti-viral compounds |
DE502006004066D1 (de) | 2006-04-19 | 2009-08-06 | Boehringer Ingelheim Pharma | Dihydrothienopyrimidine zur behandlung von entzündlichen erkrankungen |
EP1847543A1 (de) | 2006-04-19 | 2007-10-24 | Boehringer Ingelheim Pharma GmbH & Co. KG | Dihydrothienopyrimidine zur Behandlung von entzündlichen Erkrankungen |
MX2008013400A (es) * | 2006-04-19 | 2008-11-10 | Astellas Pharma Inc | Derivado de azolcarboxamida. |
MX2008016523A (es) * | 2006-06-30 | 2009-01-19 | Astrazeneca Ab | Derivados de pirimidina utiles en el tratamiento de cancer. |
AU2007269540B2 (en) * | 2006-07-05 | 2013-06-27 | Exelixis, Inc. | Methods of using IGF1R and Abl kinase modulators |
EP2469282A1 (en) * | 2006-09-08 | 2012-06-27 | University of Oxford | Clinical diagnosis of hepatic fibrosis using a novel panel of human serum protein biomarkers |
MX2009003793A (es) | 2006-10-09 | 2009-12-14 | Takeda Pharmaceutical | Inhibidores de cinasa. |
TW200823196A (en) * | 2006-11-01 | 2008-06-01 | Astrazeneca Ab | New use |
EP2094276A4 (en) | 2006-12-20 | 2011-01-05 | Abbott Lab | ANTIVIRAL COMPOUNDS |
US9187485B2 (en) | 2007-02-02 | 2015-11-17 | Baylor College Of Medicine | Methods and compositions for the treatment of cancer and related hyperproliferative disorders |
WO2008129255A1 (en) * | 2007-04-18 | 2008-10-30 | Astrazeneca Ab | 5-aminopyrazol-3-yl-3h-imidazo [4,5-b] pyridine derivatives and their use for the treatment of cancer |
UY31048A1 (es) * | 2007-04-25 | 2008-11-28 | Astrazeneca Ab | Nuevos compuestos de pirimidina y usos de los mismos |
UA99459C2 (en) | 2007-05-04 | 2012-08-27 | Астразенека Аб | 9-(pyrazol-3-yl)- 9h-purine-2-amine and 3-(pyraz0l-3-yl)-3h-imidazo[4,5-b]pyridin-5-amine derivatives and their use for the treatment of cancer |
EP2173752B2 (en) | 2007-06-13 | 2022-07-13 | Incyte Holdings Corporation | Salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo(2,3-d)pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile |
WO2009013545A2 (en) * | 2007-07-26 | 2009-01-29 | Astrazeneca Ab | Chemical compounds |
WO2009019518A1 (en) * | 2007-08-09 | 2009-02-12 | Astrazeneca Ab | Pyrimidine compounds having a fgfr inhibitory effect |
WO2009050242A2 (de) | 2007-10-19 | 2009-04-23 | Boehringer Ingelheim International Gmbh | Heterocyclus-substituierte piperazino-dihydrothienopyrimidine |
ATE537175T1 (de) | 2007-10-19 | 2011-12-15 | Boehringer Ingelheim Int | Neue piperazino-dihydrothienopyrimidin-derivate |
CA2705414C (en) | 2007-10-19 | 2016-05-24 | Boehringer Ingelheim International Gmbh | Substituted piperidino-dihydrothienopyrimidines |
AU2008314922B2 (en) | 2007-10-24 | 2013-08-29 | Astellas Pharma Inc. | Azolecarboxamide compound or salt thereof |
WO2009056886A1 (en) * | 2007-11-01 | 2009-05-07 | Astrazeneca Ab | Pyrimidine derivatives and their use as modulators of fgfr activity |
BRPI0820544A2 (pt) | 2007-11-16 | 2015-06-16 | Incyte Corp | 4-pirazolil-n-arilpirimidin-2-aminas e pirazolil-n-heteroarilpirimidin-2-aminas como inibidores de janus cinase |
WO2009088054A1 (ja) | 2008-01-11 | 2009-07-16 | Astellas Pharma Inc. | 精巣の疼痛又は不快感行動及び頻尿併発モデル動物 |
EP2288602A1 (en) * | 2008-06-11 | 2011-03-02 | AstraZeneca AB | Tricyclic 2,4-diamin0-l,3,5-triazine derivatives useful for the treatment of cancer and myeloproliferative disorders |
EP2350075B1 (en) | 2008-09-22 | 2014-03-05 | Array Biopharma, Inc. | Substituted imidazo[1,2b]pyridazine compounds as trk kinase inhibitors |
BRPI0919488A2 (pt) * | 2008-09-30 | 2015-12-01 | Astrazeneca Ab | composto, uso de um composto, método para tratar câncer em um animal de sangue quente, composição farmacêutica, e, processo para preparar um composto |
HUE057625T2 (hu) | 2008-10-22 | 2022-05-28 | Array Biopharma Inc | TRK kináz inhibitor szubsztituált pirazolo[1,5-a]pirimidin vegyületek |
EP2210879A1 (de) * | 2008-12-30 | 2010-07-28 | Bayer CropScience AG | Pyrimidinderivate und ihre Verwendung zur Bekämpfung unerwünschten Pflanzenwachstums |
WO2010114894A1 (en) | 2009-03-31 | 2010-10-07 | Arqule, Inc. | Substituted heterocyclic compounds |
EP2430451B1 (en) * | 2009-05-14 | 2014-08-13 | The Chancellors, Masters and Scholars of the University of Oxford | Clinical diagnosis of hepatic fibrosis / cirrhosis using low abundant human plasma protein biomarkers |
TWI484962B (zh) | 2009-05-22 | 2015-05-21 | Incyte Corp | 作為jak抑制劑之3-〔4-(7h-吡咯并〔2,3-d〕嘧啶-4-基)-1h-吡唑-1-基〕辛烷或庚腈 |
US8716303B2 (en) | 2009-05-22 | 2014-05-06 | Incyte Corporation | N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors |
AR077468A1 (es) | 2009-07-09 | 2011-08-31 | Array Biopharma Inc | Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa |
WO2011018517A1 (en) | 2009-08-14 | 2011-02-17 | Boehringer Ingelheim International Gmbh | Regioselective preparation of 2-amino-5-trifluoromethylpyrimidine derivatives |
US8933227B2 (en) | 2009-08-14 | 2015-01-13 | Boehringer Ingelheim International Gmbh | Selective synthesis of functionalized pyrimidines |
US9249145B2 (en) | 2009-09-01 | 2016-02-02 | Incyte Holdings Corporation | Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors |
KR102354472B1 (ko) | 2010-03-10 | 2022-01-21 | 인사이트 홀딩스 코포레이션 | Jak1 저해제로서의 피페리딘4일 아제티딘 유도체 |
WO2011146336A1 (en) | 2010-05-20 | 2011-11-24 | Array Biopharma Inc. | Macrocyclic compounds as trk kinase inhibitors |
EP2574168B9 (en) | 2010-05-21 | 2016-10-05 | Incyte Holdings Corporation | Topical formulation for a jak inhibitor |
DE102010025663A1 (de) * | 2010-06-30 | 2012-01-05 | Karl-Heinz Glüsenkamp | Neue beta-Aminoaldehyd-Derivate, Verfahren zu ihrer Herstellung und ihre chemische Verwendung als reaktive Intermediate |
AU2011305525B2 (en) | 2010-09-22 | 2016-08-18 | Arena Pharmaceuticals, Inc. | Modulators of the GPR119 receptor and the treatment of disorders related thereto |
WO2012068450A1 (en) | 2010-11-19 | 2012-05-24 | Incyte Corporation | Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors |
JP5917544B2 (ja) | 2010-11-19 | 2016-05-18 | インサイト・ホールディングス・コーポレイションIncyte Holdings Corporation | Jak阻害剤としての複素環置換ピロロピリジンおよびピロロピリミジン |
RU2606131C2 (ru) * | 2011-05-13 | 2017-01-10 | Эррэй Биофарма Инк. | СОЕДИНЕНИЯ ПИРРОЛИДИНИЛМОЧЕВИНЫ И ПИРРОЛИДИНИЛТИОМОЧЕВИНЫ КАК ИНГИБИТОРЫ КИНАЗЫ TrkA |
JP5876146B2 (ja) | 2011-06-20 | 2016-03-02 | インサイト・ホールディングス・コーポレイションIncyte Holdings Corporation | Jak阻害剤としてのアゼチジニルフェニル、ピリジル、またはピラジニルカルボキサミド誘導体 |
TW201313721A (zh) | 2011-08-18 | 2013-04-01 | Incyte Corp | 作為jak抑制劑之環己基氮雜環丁烷衍生物 |
US20130059866A1 (en) | 2011-08-24 | 2013-03-07 | Boehringer Ingelheim International Gmbh | Novel piperidino-dihydrothienopyrimidine sulfoxides and their use for treating copd and asthma |
US9802954B2 (en) | 2011-08-24 | 2017-10-31 | Boehringer Ingelheim International Gmbh | Piperidino-dihydrothienopyrimidine sulfoxides and their use for treating COPD and asthma |
KR20140062079A (ko) * | 2011-08-25 | 2014-05-22 | 에프. 호프만-라 로슈 아게 | 세린/트레오닌 pak1 억제제 |
UA111854C2 (uk) | 2011-09-07 | 2016-06-24 | Інсайт Холдінгс Корпорейшн | Способи і проміжні сполуки для отримання інгібіторів jak |
JP2015504876A (ja) | 2011-12-22 | 2015-02-16 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | セリン/トレオニンキナーゼ阻害剤としての2,4−ジアミン−ピリミジン誘導体 |
EP2852586A1 (en) | 2012-03-16 | 2015-04-01 | Axikin Pharmaceuticals, Inc. | 3,5-diaminopyrazole kinase inhibitors |
AR091079A1 (es) | 2012-05-18 | 2014-12-30 | Incyte Corp | Derivados de pirrolopirimidina y pirrolopiridina sustituida con piperidinilciclobutilo como inhibidores de jak |
TWI585088B (zh) | 2012-06-04 | 2017-06-01 | 第一三共股份有限公司 | 作爲激酶抑制劑之咪唑并[1,2-b]嗒衍生物 |
HUE055894T2 (hu) | 2012-11-15 | 2021-12-28 | Incyte Holdings Corp | A ruxolitinib nyújtott felszabadulású dózisformái |
CN103012428A (zh) * | 2013-01-08 | 2013-04-03 | 中国药科大学 | 4-(五元杂环并嘧啶/吡啶取代)氨基-1H-3-吡唑甲酰胺类CDK/Aurora双重抑制剂及其用途 |
PE20151902A1 (es) | 2013-03-06 | 2015-12-26 | Incyte Corp | Proceso e intermedios para hacer un inhibidor de jak |
EP3721873A1 (en) | 2013-08-07 | 2020-10-14 | Incyte Corporation | Sustained release dosage forms for a jak1 inhibitor |
NZ631142A (en) | 2013-09-18 | 2016-03-31 | Axikin Pharmaceuticals Inc | Pharmaceutically acceptable salts of 3,5-diaminopyrazole kinase inhibitors |
WO2015184305A1 (en) | 2014-05-30 | 2015-12-03 | Incyte Corporation | TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1 |
TWI746426B (zh) | 2014-11-16 | 2021-11-21 | 美商亞雷生物製藥股份有限公司 | (S)-N-(5-((R)-2-(2,5-二氟苯基)-吡咯啶-1-基)-吡唑并[1,5-a]嘧啶-3-基)-3-羥基吡咯啶-1-甲醯胺硫酸氫鹽結晶型 |
AU2015369690B2 (en) | 2014-12-23 | 2019-01-17 | SMA Therapeutics Inc. | 3,5-diaminopyrazole kinase inhibitors |
AU2016205361C1 (en) | 2015-01-06 | 2021-04-08 | Arena Pharmaceuticals, Inc. | Methods of treating conditions related to the S1P1 receptor |
EA201792679A1 (ru) | 2015-06-01 | 2018-06-29 | Локсо Онколоджи, Инк. | Способы диагностики и лечения злокачественной опухоли |
IL285890B (en) | 2015-06-22 | 2022-07-01 | Arena Pharm Inc | Slate-free crystal of the arginine salt of (Ar)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-4,3,2,1-tetrahydro-cyclopent[b]indole-3-yl ) acetic acid |
HUE053067T2 (hu) | 2015-07-16 | 2021-06-28 | Array Biopharma Inc | Helyettesített pirazolo[1,5-A]piridin vegyületek, mint RET kináz inhibitorok |
RU2744852C2 (ru) | 2015-10-26 | 2021-03-16 | Локсо Онколоджи, Инк. | Точечные мутации в устойчивых к ингибитору trk злокачественных опухолях и связанные с ними способы |
US10045991B2 (en) | 2016-04-04 | 2018-08-14 | Loxo Oncology, Inc. | Methods of treating pediatric cancers |
WO2017176751A1 (en) | 2016-04-04 | 2017-10-12 | Loxo Oncology, Inc. | Liquid formulations of (s)-n-(5-((r)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide |
MA44612A (fr) | 2016-04-04 | 2019-02-13 | Loxo Oncology Inc | Méthodes de traitement de cancers pédiatriques |
JP7443057B2 (ja) | 2016-05-18 | 2024-03-05 | ロクソ オンコロジー, インコーポレイテッド | (S)-N-(5-((R)-2-(2,5-ジフルオロフェニル)ピロリジン-1-イル)-ピラゾロ[1,5-a]ピリミジン-3-イル)-3-ヒドロキシピロリジン-1-カルボキサミドの調製 |
SG11201811161YA (en) | 2016-07-14 | 2019-01-30 | Pfizer | Novel pyrimidine carboxamides as inhibitors of vanin-1 enzyme |
TWI704148B (zh) | 2016-10-10 | 2020-09-11 | 美商亞雷生物製藥股份有限公司 | 作為ret激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物 |
JOP20190077A1 (ar) | 2016-10-10 | 2019-04-09 | Array Biopharma Inc | مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret |
JOP20190092A1 (ar) | 2016-10-26 | 2019-04-25 | Array Biopharma Inc | عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها |
WO2018136663A1 (en) | 2017-01-18 | 2018-07-26 | Array Biopharma, Inc. | Ret inhibitors |
WO2018136661A1 (en) | 2017-01-18 | 2018-07-26 | Andrews Steven W | SUBSTITUTED PYRAZOLO[1,5-a]PYRAZINE COMPOUNDS AS RET KINASE INHIBITORS |
US11534424B2 (en) | 2017-02-16 | 2022-12-27 | Arena Pharmaceuticals, Inc. | Compounds and methods for treatment of primary biliary cholangitis |
JOP20190213A1 (ar) | 2017-03-16 | 2019-09-16 | Array Biopharma Inc | مركبات حلقية ضخمة كمثبطات لكيناز ros1 |
TWI812649B (zh) | 2017-10-10 | 2023-08-21 | 美商絡速藥業公司 | 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物 |
TWI791053B (zh) | 2017-10-10 | 2023-02-01 | 美商亞雷生物製藥股份有限公司 | 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物 |
US20190247398A1 (en) | 2017-10-26 | 2019-08-15 | Array Biopharma Inc. | Formulations of a macrocyclic trk kinase inhibitor |
AR113922A1 (es) | 2017-12-08 | 2020-07-01 | Incyte Corp | Terapia de combinación de dosis baja para el tratamiento de neoplasias mieloproliferativas |
WO2019143977A1 (en) | 2018-01-18 | 2019-07-25 | Array Biopharma Inc. | Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors |
WO2019143991A1 (en) | 2018-01-18 | 2019-07-25 | Array Biopharma Inc. | SUBSTITUTED PYRAZOLO[3,4-d]PYRIMIDINE COMPOUNDS AS RET KINASE INHIBITORS |
CA3087972C (en) | 2018-01-18 | 2023-01-10 | Array Biopharma Inc. | Substituted pyrazolyl[4,3-c]pyridinecompounds as ret kinase inhibitors |
DK3746429T3 (da) | 2018-01-30 | 2022-05-02 | Incyte Corp | Fremgangsmåder til fremstilling af (1-(3-fluor-2-(trifluormethyl)isonicotinyl)piperidin-4-on) |
EP3773725A1 (en) | 2018-03-29 | 2021-02-17 | Loxo Oncology Inc. | Treatment of trk-associated cancers |
IL277538B1 (en) | 2018-03-30 | 2024-05-01 | Incyte Corp | Use of JAK inhibitors to treat hidradenitis suppurativa |
CA3224945A1 (en) | 2018-07-31 | 2020-02-06 | Loxo Oncology, Inc. | Spray-dried dispersions, formulations, and polymorphs of (s)-5-amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-(1,1,1-trifluoropropan-2-yl)-1h-pyrazole-4-carboxamide |
JP2022500383A (ja) | 2018-09-10 | 2022-01-04 | アレイ バイオファーマ インコーポレイテッド | Retキナーゼ阻害剤としての縮合複素環式化合物 |
US20220081438A1 (en) | 2018-12-19 | 2022-03-17 | Array Biopharma Inc. | Substituted pyrazolo[1,5-a]pyridine compounds as inhibitors of fgfr tyrosine kinases |
EP3898615A1 (en) | 2018-12-19 | 2021-10-27 | Array Biopharma, Inc. | 7-((3,5-dimethoxyphenyl)amino)quinoxaline derivatives as fgfr inhibitors for treating cancer |
BR112021018168B1 (pt) | 2019-03-21 | 2023-11-28 | Onxeo | Composição farmacêutica, combinação e kit compreendendo uma molécula dbait e um inibidor de quinase para o tratamento de câncer |
KR20220098759A (ko) | 2019-11-08 | 2022-07-12 | 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) | 키나제 억제제에 대해 내성을 획득한 암의 치료 방법 |
WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
US11833155B2 (en) | 2020-06-03 | 2023-12-05 | Incyte Corporation | Combination therapy for treatment of myeloproliferative neoplasms |
WO2022101343A1 (de) | 2020-11-16 | 2022-05-19 | Credoxys GmbH | Cer-ethylendiaminketonartige - und cer-salenartige-komplexe und deren verwendung in der organischen elektronik |
JP2024511012A (ja) * | 2021-03-24 | 2024-03-12 | アトス セラピューティクス,インコーポレイテッド | キナーゼ関連疾患の処置のための小分子 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001060816A1 (en) * | 2000-02-17 | 2001-08-23 | Amgen Inc. | Kinase inhibitors |
SE0104140D0 (sv) * | 2001-12-07 | 2001-12-07 | Astrazeneca Ab | Novel Compounds |
-
2004
- 2004-11-12 MY MYPI20044727A patent/MY141220A/en unknown
- 2004-11-15 KR KR1020067011985A patent/KR101192939B1/ko not_active IP Right Cessation
- 2004-11-15 EP EP04798505A patent/EP1686999B1/en active Active
- 2004-11-15 AT AT04798505T patent/ATE435017T1/de active
- 2004-11-15 NZ NZ547938A patent/NZ547938A/en not_active IP Right Cessation
- 2004-11-15 BR BRPI0416605-1A patent/BRPI0416605A/pt not_active IP Right Cessation
- 2004-11-15 KR KR1020127017241A patent/KR20120094084A/ko not_active Application Discontinuation
- 2004-11-15 JP JP2006540576A patent/JP4942486B2/ja not_active Expired - Fee Related
- 2004-11-15 WO PCT/GB2004/004784 patent/WO2005049033A1/en active Application Filing
- 2004-11-15 DK DK04798505T patent/DK1686999T3/da active
- 2004-11-15 US US10/595,807 patent/US20070142413A1/en not_active Abandoned
- 2004-11-15 PT PT04798505T patent/PT1686999E/pt unknown
- 2004-11-15 RU RU2006121337/04A patent/RU2413727C2/ru not_active IP Right Cessation
- 2004-11-15 AU AU2004290948A patent/AU2004290948B2/en not_active Ceased
- 2004-11-15 PL PL04798505T patent/PL1686999T3/pl unknown
- 2004-11-15 SI SI200431205T patent/SI1686999T1/sl unknown
- 2004-11-15 ES ES04798505T patent/ES2328042T3/es active Active
- 2004-11-15 CA CA2545527A patent/CA2545527C/en not_active Expired - Fee Related
- 2004-11-15 DE DE602004021844T patent/DE602004021844D1/de active Active
- 2004-11-17 TW TW093135262A patent/TWI343383B/zh not_active IP Right Cessation
- 2004-11-17 UY UY28623A patent/UY28623A1/es not_active Application Discontinuation
- 2004-11-17 AR ARP040104237A patent/AR046779A1/es not_active Application Discontinuation
-
2006
- 2006-05-08 IL IL175487A patent/IL175487A/en not_active IP Right Cessation
- 2006-05-15 NO NO20062188A patent/NO20062188L/no not_active Application Discontinuation
- 2006-12-11 HK HK06113587.6A patent/HK1092723A1/xx not_active IP Right Cessation
-
2009
- 2009-08-21 HR HR20090454T patent/HRP20090454T1/hr unknown
- 2009-09-16 CY CY20091100953T patent/CY1110498T1/el unknown
-
2010
- 2010-02-25 US US12/712,659 patent/US20100152219A1/en not_active Abandoned
-
2011
- 2011-11-07 JP JP2011243454A patent/JP2012082198A/ja not_active Withdrawn
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK1686999T3 (da) | Pyrazolderivater som inhibitorer af receptortyrosinkinaser | |
DK1667991T3 (da) | Quinazolinderivater som tyrosinkinaseinhibitorer | |
DK1532138T3 (da) | Inhibitorer af tyrosinkinaser | |
DK1786799T3 (da) | Hidtil ukendte phenylaminopyrimidinderivater som inhibitorer af bcr-abl-kinase | |
DK1562589T3 (da) | Diaminotriazoler der er nyttige som inhibitorer af proteinkinaser | |
DK1463506T3 (da) | Substituerede quinazolin-derivater som inhibitorer af aurora-kinaser | |
DK1811998T3 (da) | Triazoler anvendelige som inhibitorer af proteinkinaser | |
DK1664043T3 (da) | Sammensætninger egnede som inhibitorer af proteinkinaser | |
DK1585749T3 (da) | Diazepinoindol-derivater som kinaseinhibitorer | |
DK1761505T3 (da) | Pyrimidin-urinstof-derivater som kinaseinhibitorer | |
DE602005025733D1 (de) | Pyrazolopyrimidinderivate als inhibitoren der cyclinabhängigen kinase | |
DK2261223T3 (da) | Pyrimidinderivater anvendt som PI-3-kinasehæmmere | |
DK2120932T3 (da) | Indazolderivater som kinasehæmmere til behandling af kræft | |
NO20091423L (no) | Pyrimidinderivater og deres anvendelse som kinaseinhibitorer | |
DK1778686T3 (da) | Triazolopyridinylsulfanylderivater som P38 MAP kinase-inhibitorer | |
DK1711481T3 (da) | Fremgangsmåde til fremstilling af 2-aminothiazol-5-aromatiske carboxamider som kinaseinhibitorer | |
DK1763517T3 (da) | Pyrimidinderivater som 11beta-HSD1-inhibitorer | |
DK1556375T3 (da) | Flavonderivater som inhibitorer af cyklinafhængige kinaser | |
IL173200A0 (en) | Piperidyl-quinazoline derivatives as tyrosine kinase inhibitors | |
NO20045220L (no) | Heterocykliske inhibitorer for kinaser | |
DK1981875T3 (da) | Substituerede indolylalkylaminoderivater som inhibitorer af histondeacetylase | |
DK1805164T3 (da) | 6-(pyridinyl)-4-pyrimidonderivater som inhibitorer af TAU 1 oroteinkinase | |
DK1740569T3 (da) | Imidazol-derivater som TAFla-inhibitorer | |
DK1711177T3 (da) | 1H-thieno-2,3-c-pyrazolderivater, der er egnede som kinase-I-inhibitorer | |
ATE393159T1 (de) | Heterobicyclische pyrazolderivate als kinaseinhibitoren |